WallStreetZenWallStreetZen

NASDAQ: ALRN
Aileron Therapeutics Inc Stock

$6.93+1.23 (+21.58%)
Updated Mar 27, 2024
ALRN Price
$6.93
Fair Value Price
$1.14
Market Cap
$31.47M
52 Week Low
$1.01
52 Week High
$7.12
P/E
-2.42x
P/B
2.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$14M
Beta
1.04
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALRN Overview

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALRN ($6.93) is overvalued by 509.61% relative to our estimate of its Fair Value price of $1.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALRN ($6.93) is not significantly undervalued (509.61%) relative to our estimate of its Fair Value price of $1.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALRN due diligence checks available for Premium users.

Be the first to know about important ALRN news, forecast changes, insider trades & much more!

ALRN News

Valuation

ALRN fair value

Fair Value of ALRN stock based on Discounted Cash Flow (DCF)
Price
$6.93
Fair Value
$1.14
Overvalued by
509.52%
ALRN ($6.93) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALRN ($6.93) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALRN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.42x
Industry
14.3x
Market
44.45x

ALRN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.81x
Industry
6.2x
ALRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALRN's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
ALRN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$12.8M
Liabilities
$1.6M
Debt to equity
0.15
ALRN's short-term assets ($12.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALRN's short-term assets ($12.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALRN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.6M
Investing
$542.0k
Financing
$0.0
ALRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALRN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALRN$31.47M+21.60%-2.42x2.81x
INKT$31.58M-2.99%-1.40x-1.75x
NTRB$31.72M+33.22%-6.04x5.55x
ACST$31.96M0.00%-0.67x0.49x
SPRB$30.45M+5.71%-0.60x0.40x

Aileron Therapeutics Stock FAQ

What is Aileron Therapeutics's quote symbol?

(NASDAQ: ALRN) Aileron Therapeutics trades on the NASDAQ under the ticker symbol ALRN. Aileron Therapeutics stock quotes can also be displayed as NASDAQ: ALRN.

If you're new to stock investing, here's how to buy Aileron Therapeutics stock.

What is the 52 week high and low for Aileron Therapeutics (NASDAQ: ALRN)?

(NASDAQ: ALRN) Aileron Therapeutics's 52-week high was $7.12, and its 52-week low was $1.01. It is currently -2.65% from its 52-week high and 586.24% from its 52-week low.

How much is Aileron Therapeutics stock worth today?

(NASDAQ: ALRN) Aileron Therapeutics currently has 4,541,167 outstanding shares. With Aileron Therapeutics stock trading at $6.93 per share, the total value of Aileron Therapeutics stock (market capitalization) is $31.47M.

Aileron Therapeutics stock was originally listed at a price of $216.00 in Jun 29, 2017. If you had invested in Aileron Therapeutics stock at $216.00, your return over the last 6 years would have been -96.79%, for an annualized return of -43.63% (not including any dividends or dividend reinvestments).

How much is Aileron Therapeutics's stock price per share?

(NASDAQ: ALRN) Aileron Therapeutics stock price per share is $6.93 today (as of Mar 27, 2024).

What is Aileron Therapeutics's Market Cap?

(NASDAQ: ALRN) Aileron Therapeutics's market cap is $31.47M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Aileron Therapeutics's market cap is calculated by multiplying ALRN's current stock price of $6.93 by ALRN's total outstanding shares of 4,541,167.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.